An interventional study of Harrison.ai Chest X-Ray Solution in Cancer, Cardiovascular and Respiratory, sponsored by NHS Greater Glasgow and Clyde. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by NHS Greater Glasgow and Clyde · Not applicable, Interventional, and Diagnostic
SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays.
We want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.
SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital.
The aim of the study is to find out if using an artificial intelligence (AI) computer programme can help doctors diagnose heart and lung problems from chest x-rays. The computer programme is made by Harrison.ai. It is approved for use in the United Kingdom (UK), United States of America (US) and the European Union (EU). Studies have been carried out previously to make sure it is safe to use and that it can detect signs of heart and lung problems.
Many people who come to ED have a chest x-ray. Chest x-rays can show signs of heart or lung problems, which might be causing a patient's symptoms. All doctors can interpret chest x-rays. However, doctors who specialise in interpreting scans (radiologists) also provide an expert report for chest x-rays, describing what they have found. It can take a long time for chest x-ray reports to come back. Sometimes, doctors might miss signs of heart or lung problems.
We want to see if using a computer programme to help doctors interpret chest x-rays could lead to more patients getting an accurate diagnosis. We want to compare how many people are diagnosed with heart or lung problems (Chronic obstructive pulmonary disease [COPD], heart failure or lung cancer) for the first time when doctors have access to the computer programme results, in comparison to when they don't.
Patients older than 18 who have a chest x-ray in ED will be included.
Patients with chest x-rays flagged by the computer programme for heart failure or COPD will be invited to an outpatient clinic for further assessment post-discharge, providing they have not been referred for testing or had testing previously.
All patients with chest x-rays flagged for lung cancer will be reviewed and acted on by the study radiologist.
The study consists of 1) a retrospective component; 2) a prospective live trial; 3) a qualitative evaluation of acceptability to patients and clinicians, and 4) a health economic analysis.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 17,000 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →NHS Greater Glasgow and Clyde is the lead sponsor of 220 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unconsented Use of Harrison CXR Algorithm in Emergency Department (ED):
Patient Focus Groups:
Clinician Focus Groups:
Diagnostic Clinic:
Exclusion Criteria:
Applies to use of unconsented CXRs:
- Patient has requested that they are removed from the study, or has objected to the use of AI in their routine clinical care and this has been subsequently upheld by the health board.
Applies to invitation to combined diagnostic clinic:
For Patient and Clinician Focus Groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chest X-ray AI results will be available to the treating clinician
Device: Harrison.ai Chest X-Ray Solution
Chest X-ray AI results will not be available to the treating clinician
Device: Harrison.ai Chest X-Ray Solution
The Harrison.ai CXR module is an AI-driven clinical decision support tool that is designed to augment clinical interpretation of CXRs. It is a Class IIb CE-marked device which is able to detect up to 124 findings on a CXR.
Proportion of patients identified with a confirmed new diagnosis of heart failure, based on subsequent clinical assessment and guideline-based investigation.
Time frame: 12 months
Duration of admission during index hospitalisation
Time frame: 12 months
Time to initiation of guideline-based, long-term therapy for Chronic obstructive pulmonary disease (COPD) and Heart Failure.
For Chronic obstructive pulmonary disease (COPD), this will be defined as first prescription of combined long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) inhaler or LABA/LAMA/inhaled corticosteroid (single or split) inhaler therapy. For Heart Failure , this will be defined as first prescription of either a) a renin-angiotensin system inhibitors, b) a beta blocker, or c) an SLGT2 inhibitor.
Time frame: 12 months
Time to diagnostic testing for Heart Failure, COPD and lung cancer (echocardiography, spirometry, CT).
Time frame: 12 months
Time to inpatient or outpatient specialist review and confirmation of lung cancer, COPD or Heart Failure
Time frame: 12 months
Acceptability of AI-supported interpretation of Chest X-Ray for Emergency Department clinicians pre and post intervention using Theoretical Framework of Acceptability (TFA)
We will ask clinicians what they think of using AI for Chest X-Rays
Time frame: Baseline and 12 months
Readmission rate within 90 days
Time frame: 3 months
Proportion of patients with new diagnosis of lung cancer detected by an AI-Chest X-Ray algorithm
Time frame: 12 months
Proportion of patients with new diagnosis of COPD detected by an AI-Chest X-Ray algorithm
Time frame: 12 months
Proportion of patients with clinically-confirmed known diagnosis of lung cancer, Heart Failure and COPD detected by an AI-Chest X-Ray algorithm
Time frame: 12 months
Percentage of Chest X-Rays not identified by an AI-CXR algorithm that have a subsequent diagnosis of Heart Failure, COPD or lung cancer within 6 months of index imaging (Emergency Department Chest X-Ray).
Time frame: 6 months
Statistical analysis of model performance e.g. sensitivity, specificity, positive and negative predictive value
Time frame: 12 months
Plan to share: Yes — The dataset will be available in NHS GGC Safe Haven whereby pseudonymised access can be granted through NHS GGC LPAC approvals, as per local GGC policy.
Supporting information: Study protocol, Clinical study report
Time frame: After publication of results
Access criteria: Bone fide collaboration request
Data sharing details ↗ · www.gla.ac.uk
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 13 months is below that.
Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Greater Glasgow and Clyde →